Search Within

Breast Medicine Service

Formats
  1. Journal Article (2206)
  2. Meeting Abstract (1680)
  3. Review (83)
  4. Book Section (69)
  5. Editorial (44)
  6. Conference Paper (28)
  7. Guidelines (27)
  8. Correspondence (16)
  9. Miscellaneous (12)
  10. Research Letter (11)
  11. Book Whole (5)
Groups
  1. Department of Medicine (4181)
  2. Solid Tumor Oncology Division (4181)
  3. Survivorship Research (2373)
  4. GSK Faculty (1516)
  5. Population Sciences Research Program (1369)
  6. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (1144)

More Groups

People
  1. Clifford Hudis (906)
  2. Larry Norton (762)
  3. Mark Robson (684)
  4. Neal Rosen (427)
  5. Andrew Seidman (319)
  6. Kenneth Offit (300)

More People

Years
  1. 2025 (130)
  2. 2024 (195)
  3. 2023 (168)
  4. 2022 (219)
  5. 2021 (236)
  6. 2020 (250)

More Years

Publications
  1. Journal of Clinical Oncology (828)
  2. Cancer Research (481)
  3. Breast Cancer Research and Treatment (170)
  4. Annals of Oncology (159)
  5. Clinical Cancer Research (132)
  6. Cancer (78)

More Publications

Publishers
  1. American Society of Clinical Oncology (880)
  2. American Association for Cancer Research (755)
  3. Springer (332)
  4. Elsevier Inc. (308)
  5. Oxford University Press (282)
  6. Nature Publishing Group (276)

More Publishers

Results (4181)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Reactivation of oncogenic signaling through mTOR inhibitors-induced feedback adaptations
    Meeting Abstract

    Rodrik-Outmezguine, V.; Chandarlapaty, S.; Poulikakos, P.; Scaltriti, M.; Baselga, J.; Rosen, N.
    Cancer Research (2012)

    Fulltext@MSK | Save
  • Bevacizumab (B) in the adjuvant treatment of breast cancer - First toxicity results from Eastern Cooperative Oncology Group trial E5103
    Meeting Abstract

    Miller, K. D.; O'Neill, A.; Dang, C.; Northfelt, D.; Gradishar, W.; Sledge, G. W.
    Cancer Research (2012)

    Fulltext@MSK | Save
  • Tolerability and efficacy of targeting both mTOR and HER2 signaling in trastuzumab-refractory HER2+ metastatic breast cancer
    Meeting Abstract

    Gajria, D.; King, T.; Pannu, H.; Sakr, R.; Modi, S.; Drullinsky, P.; Syldor, A.; Patil, S.; Seidman, A.; Norton, L.; more...
    Cancer Research (2012)

    Fulltext@MSK | Save
  • Phase II trial of dasatinib in combination with weekly paclitaxel for patients with metastatic breast carcinoma
    Meeting Abstract

    Morris, P. G.; Lake, D.; McArthur, H. L.; Gilewski, T.; Dang, C.; Chaim, J.; Patl, S.; Lim, K.; Norton, L.; Hudis, C. A.; more...
    Cancer Research (2012)

    Fulltext@MSK | Save
  • Molecular predictors for type of recurrence following conservative treatment for DCIS
    Meeting Abstract

    Sakr, R. A.; Andrade, V. P.; Chandarlapaty, S.; Giovanni, C.; Giri, D.; Heguy, A.; De Brot, M.; Olvera, N.; Muhsen, S.; Koslow, S.; more...
    Cancer Research (2012)

    Fulltext@MSK | Save
  • Phase II study of pertuzumab, trastuzumab, and weekly paclitaxel in patients with metastatic HER2-overexpressing metastatic breast cancer
    Meeting Abstract

    Datko, F.; D'Andrea, G.; Dickler, M.; Theodoulou, M.; Goldfarb, S.; Lake, D.; Fornier, M.; Modi, S.; Sklarin, N.; Comen, E.; more...
    Cancer Research (2012)

    Fulltext@MSK | Save
  • Work status and financial stability during treatment for early breast cancer: A pilot study of an ethnically diverse sample
    Meeting Abstract

    Eberle, C. E.; Min, S. H.; Jung, S.; Ramirez, J.; Patil, S.; Gany, F.; Blinder, V. S.
    Cancer Research (2012)

    Fulltext@MSK | Save
  • PIK3CA mutations associate with decreased Ki67 in early stage breast cancer (BC) and better outcomes in patients even among those with low Ki67 tumors
    Meeting Abstract

    Datko, F. M.; Patil, S.; Kalinsky, K.; Asher, M.; Wen, Y. H.; Hedvat, C.; Moynahan, M. E.
    Cancer Research (2012)

    Fulltext@MSK | Save
  • A randomized, phase 2 study of the poly (ADP-ribose) polymerase (PARP) inhibitor veliparib (ABT-888) in combination with temozolomide (TMZ) or in combination with carboplatin (C) and paclitaxel (P) versus placebo plus C/P in subjects with BRCA1 or BRACA2 mutation and metastatic breast cancer
    Meeting Abstract

    Isakoff, S. J.; Pulhalla, S.; Shepherd, S. P.; Falotico, N.; Kaufman, B.; Friedlander, M.; Robson, M.; Domchek, S.; Garber, J.; McKeegan, E.; more...
    Cancer Research (2012)

    Fulltext@MSK | Save
  • PAM50 gene signature is prognostic for breast cancer patients treated with adjuvant anthracycline and taxane based chemotherapy
    Meeting Abstract

    Liu, M. C.; Pitcher, B. N.; Mardis, E. R.; Davies, S. R.; Snider, J. E.; Vickery, T.; Reed, J. P.; DeSchryver, K.; Singh, B.; Friedman, P. N.; more...
    Cancer Research (2012)

    Fulltext@MSK | Save